<DOC>
	<DOCNO>NCT02949128</DOCNO>
	<brief_summary>The purpose study assess efficacy ALXN1210 control disease activity adolescent adult patient aHUS previously use complement inhibitor .</brief_summary>
	<brief_title>Single Arm Study ALXN1210 Complement Inhibitor Treatment-Naïve Adult Adolescent Patients With Atypical Hemolytic Uremic Syndrome ( aHUS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>1 . Male female ≥ 12 year age weigh ≥ 40 kg time consent . 2 . Evidence thrombotic microangiopathy ( TMA ) , include low platelet count , hemolysis ( break red blood cell inside blood vessel ) , decrease kidney function 3 . Documented meningococcal vaccination 3 year prior dose , 18 also require vaccination Streptococcus pneumoniae Haemophilus influenzae 4 . Female patient childbearing potential must use highly effective contraception start screen continue least 8 month last dose ALXN1210 1 . ADAMTS13 deficiency ( Activity &lt; 5 % ) 2 . Shiga toxinrelated hemolytic uremic syndrome ( STECHUS ) 3 . Positive direct Coombs test 4 . Pregnancy breastfeed 5 . Identified drug exposure relate hemolytic uremic syndrome ( HUS ) 6 . Bone marrow transplant ( BMT ) /hematopoietic stem cell transplant ( HSCT ) within last 6 month prior start Screening 7 . HUS related vitamin B12 deficiency 8 . Systemic sclerosis ( scleroderma ) , systemic lupus erythematosus ( SLE ) , antiphospholipid antibody positivity syndrome 9 . Chronic dialysis ( defined dialysis regular basis renal replacement therapy ESKD )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>